Home World News EMA Recommends Granting a Marketing Authorisation for Lurbinectedin World News EMA Recommends Granting a Marketing Authorisation for Lurbinectedin By Ogkologos - April 30, 2026 293 0 Facebook Twitter Google+ Pinterest WhatsApp It is indicated for the maintenance treatment of adult patients with extensive-stage small cell lung cancer Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Adding Tremelimumab to Durvalumab and Chemotherapy Provides Survival Benefit for Patients... November 15, 2022 Perioperative Durvalumab Plus FLOT Improves OS in Patients with Resectable Gastric... September 15, 2026 EMA Recommends Granting a Marketing Authorisation for Elinzanetant September 26, 2025 Eflornithine Plus Sulindac Not Superior to Either Drug Alone in FAP September 15, 2020 Load more HOT NEWS 2022 ASCO Annual Meeting Research Round Up: Advances in Treating Genitourinary... Curbing Production of Immune Checkpoint Protein Slows Liver Cancer in Mice Breast Cancer Survivor Given 12 Months to Live After Left Side... FDA Approves Isatuximab-irfc for Subcutaneous Injection for Multiple Myeloma Indications
